Phase II trial of anetumab ravtansine (BAY 94-9343) in patients with advanced or metastatic malignant pleural mesothelioma (MPM) overexpressing mesothelin after first line treatment with platinum in combination with pemetrexed

Trial Profile

Phase II trial of anetumab ravtansine (BAY 94-9343) in patients with advanced or metastatic malignant pleural mesothelioma (MPM) overexpressing mesothelin after first line treatment with platinum in combination with pemetrexed

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs Anetumab ravtansine (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 12 Mar 2016 There is one more trial (CTP 263551) similar to this trial.Trial data reported in CTP 263551 reports about BAY 94-9343 as primary drug and Vinorelbine as active comparator, as reported per EudraCT and CT.gov sources. But UKCRN 19468 record does not mention about use of "Vinorelbine" in trial.So as of now I have created this record. In future, if any amendment in UKCRN record (269009) suggests use of "Vinorelbine" this CTP(269009) need to be merged with CTP (263551).
    • 12 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top